Published in Microvasc Res on September 17, 2011
Functional genomic annotation of genetic risk loci highlights inflammation and epithelial biology networks in CKD. J Am Soc Nephrol (2014) 1.01
Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res (2014) 0.84
TEM7 (PLXDC1), a key prognostic predictor for resectable gastric cancer, promotes cancer cell migration and invasion. Am J Cancer Res (2015) 0.76
Endothelial progenitor cells contribute to the development of ovarian carcinoma tumor blood vessels. Oncol Lett (2014) 0.75
Biomarkers Discovery for Colorectal Cancer: A Review on Tumor Endothelial Markers as Perspective Candidates. Dis Markers (2016) 0.75
Averting biodiversity collapse in tropical forest protected areas. Nature (2012) 4.46
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93
Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol (2007) 2.69
Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol (2004) 1.71
Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res (2004) 1.68
Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget (2012) 1.67
Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res (2003) 1.67
Treatment of malignant gastroduodenal obstruction with a nitinol self-expanding metal stent: an international prospective multicentre registry. Dig Liver Dis (2011) 1.64
Properties of bisphosphonates in the 13762 rat mammary carcinoma model of tumor-induced bone resorption. Clin Cancer Res (2003) 1.50
Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol (2005) 1.44
Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther (2013) 1.38
Identification of a human NF-kappaB-activating protein, TAB3. Proc Natl Acad Sci U S A (2004) 1.37
Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinoma. Clin Cancer Res (2008) 1.35
LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol (2003) 1.29
Murine endothelial cell lines as models of tumor endothelial cells. Clin Cancer Res (2004) 1.27
Endothelial precursor cells as a model of tumor endothelium: characterization and comparison with mature endothelial cells. Cancer Res (2003) 1.26
Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng (2008) 1.23
Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularization. Microvasc Res (2008) 1.22
Identification of genes expressed in malignant cells that promote invasion. Cancer Res (2003) 1.20
Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. Int J Oncol (2009) 1.17
Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy. Cancer Res (2005) 1.16
Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine. Nat Chem Biol (2010) 1.11
TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence. PLoS One (2011) 1.08
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function. Mol Cancer Ther (2006) 1.06
Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget (2011) 1.06
Netrin-4 regulates angiogenic responses and tumor cell growth. Exp Cell Res (2008) 1.05
Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease. Springerplus (2012) 1.05
Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk Lymphoma (2010) 1.04
Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model. Cancer Chemother Pharmacol (2003) 1.04
Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248. Mol Cancer Ther (2008) 1.03
Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol (2003) 1.02
Identification of a binding partner for the endothelial cell surface proteins TEM7 and TEM7R. Cancer Res (2004) 0.99
Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type. Int J Gynecol Pathol (2013) 0.98
When will adolescents tell someone about dating violence victimization? Violence Against Women (2008) 0.95
Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling. Int J Oncol (2011) 0.94
The promise of antibody-drug conjugates. N Engl J Med (2012) 0.94
Endosialin expression in side populations in human sarcoma cell lines. Oncol Lett (2011) 0.92
Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res (2009) 0.92
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model. Prostate (2007) 0.92
Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. Liver Transpl (2011) 0.91
An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res (2002) 0.91
Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα. J Med Chem (2013) 0.91
Expression of TMPRSS4 in non-small cell lung cancer and its modulation by hypoxia. Int J Oncol (2012) 0.91
The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution. Int J Oncol (2008) 0.90
Health outcomes and green renovation of affordable housing. Public Health Rep (2011) 0.90
Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease. PLoS One (2012) 0.89
TGF-beta in cancer and as a therapeutic target. Biochem Pharmacol (2006) 0.89
Placental growth factor upregulation is a host response to antiangiogenic therapy. Clin Cancer Res (2011) 0.88
Characteristics of human Ewing/PNET sarcoma models. Ann Saudi Med (2011) 0.87
Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence. Exp Cell Res (2009) 0.87
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008. Clin Cancer Res (2009) 0.86
Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282. Mol Cancer Ther (2011) 0.86
Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl (2003) 0.85
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors. Mol Cancer Ther (2008) 0.85
Troponin I inhibits capillary endothelial cell proliferation by interaction with the cell's bFGF receptor. Microvasc Res (2002) 0.83
Glomerulopathy in the KK.Cg-A(y) /J mouse reflects the pathology of diabetic nephropathy. J Diabetes Res (2013) 0.83
Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs. Int J Oncol (2009) 0.83
Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents. Cancer Chemother Pharmacol (2009) 0.82